Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROVENT: PRV-101 Phase 1 in Healthy Adults
NCT04690426Phase 1Completed
- Sponsor
- Provention Bio
- Start
- Dec 2020
- Primary completion
- Dec 2021
- Modality
- Prophylactic Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PRV-101 in coxsackievirus B infection (4 cohorts), sponsored by Provention Bio. Primary endpoint: Incidence and severity of treatment-emergent adverse events at 32 weeks. Started Dec 2020; status: completed.
02
Drugs
PRV-101
03
Conditions
coxsackievirus B infection
Beyond the preview
Go deeper on NCT04690426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04690426.